Skip to main navigation Skip to search Skip to main content

Research progress of new anticancer drug lobaplatin in treatment of metastatic breast cancer

  • Xu Sun
  • , Dong Hu Sui
  • , Bing He Xu
  • Guizhou Yibai Pharmaceutical Co.Ltd

Research output: Contribution to journal › Review article › peer-review

Abstract

As the third generation platinum antitumor drug with independent intellectual property rights,a number of basic and clinical research shows lobaplatin can effectively inhibit the proliferation of human breast cancer cell lines including triple-negative breast cancer in vivo. Compared with the cisplatin-based regimens, lobaplatin-based regimens have similar efficacy, and better safety profde.It becomes the new treatment option of metastatic breast cancer, and remains to he further study to optimize clinical rational drug use.

Original languageEnglish
Pages (from-to)646-648
Number of pages3
JournalCancer Research and Clinic
Volume25
Issue number9
DOIs
StatePublished - 28 Sep 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Clinical research
  • Lobaplatin
  • Metastatic breast cancer
  • Pharmacodynamics

Fingerprint

Dive into the research topics of 'Research progress of new anticancer drug lobaplatin in treatment of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this